Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

Cortes_N_PLoS_Negl_Trop_Dis_2020.pdf (1.07 MB)

Document type

Article

Version

Published version

Publication date

2020

Publication license

cc by (c) Cortes Serra, Nuria et al, 2020
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/183635

Strengthening the Bolivian pharmacovigilance system: New surveillance strategies to improve care for Chagas disease and tuberculosis.

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

http://dx.doi.org/ 10.1371/journal.pntd.0008370

Abstract

"Chagas disease (CD) and tuberculosis (TB) are important health problems in Bolivia. Current treatments for both infections require a long period of time, and adverse drug reactions (ADRs) are frequent. This study aims to strengthen the Bolivian pharmacovigilance system, focusing on CD and TB. A situation analysis of pharmacovigilance in the Department of Cochabamba was performed. The use of a new local case report form (CRF) was implemented, together with the CRF established by the Unidad de Medicamentos y Tecnolog\xC3\xADa en Salud (UNIMED), in several healthcare centers. Training and follow-up on drug safety monitoring and ADR reporting was provided to all health professionals involved in CD and TB treatment. A comparative analysis of the reported ADRs using the CRF provided by UNIMED, the new CRF proposal, and medical records, was also performed. Our results showed that out of all patients starting treatment for CD, 37.9% suffered ADRs according to the medical records, and 25.3% of them were classified as moderate/severe (MS). Only 47.4% of MS ADRs were reported to UNIMED. Regarding TB treatment, 9.9% of all patients suffered ADRs, 44% of them were classified as MS, and 75% of MS ADRs were reported to UNIMED. These findings show that the reinforcement of the Bolivian pharmacovigilance system is an ambitious project that should involve a long-term perspective and the engagement of national health workers and other stakeholders at all levels. Continuity and perseverance are essential to achieve a solid ADR reporting system, improving patient safety, drug efficacy and adherence to treatment."

Subject

Malaltia de Chagas, Tuberculosi, Bolívia

Subject (English)

Chagas' disease, Tuberculosis, Bolivia

Citation

Collections

Articles publicats en revistes (ISGlobal)

Citation

CORTES SERRA, Nuria, et al. Strengthening the Bolivian pharmacovigilance system: New
surveillance strategies to improve care for Chagas disease and
tuberculosis. PLoS Neglected Tropical Diseases. 2020. Vol.  vol 14, num. num. ISSN 1935-2735. [consulted: 14 of August of 2026]. Available at: https://hdl.handle.net/2445/183635

Export metadata

JSON - METS

Share record